If you have been reading about Stability and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-01. Numbers and descriptions here follow the published literature rather than marketing material.
Solid material is typically kept as a lyophilised powder in a sealed, light-protected container at minus 20 degrees Celsius, with desiccant where humidity is high. Working solutions are often prepared fresh, aliquoted and frozen to avoid repeated freeze-thaw cycles. Glassware and buffers are checked for trace metal contamination, since other transition metals can displace copper. Records of lot number, reconstitution date and storage temperature help trace unexpected colour changes. Blue colour itself is not a reliable purity test, because partly degraded solutions can remain visibly coloured.
Identity and purity are normally checked by reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry. The peptide absorbs in the ultraviolet region, and the copper complex also shows a broad visible absorption band that can be followed spectroscopically. Copper content is measured separately, for example by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy, because the peptide assay alone does not confirm how much metal is bound. Purity figures therefore need a stated basis: peptide peak area, copper content, or both.
Aqueous solutions of GHK-Cu are less stable than the dry powder. The peptide backbone is vulnerable to hydrolysis at extreme pH, and copper can be stripped from the complex by strong chelating agents such as EDTA or citrate. Oxidising agents and high concentrations of ascorbic acid can reduce copper(II) and change the complex, which is one reason formulators often keep such ingredients in separate phases. How quickly these changes occur under real storage conditions depends on pH, buffer, temperature and packaging, and quantitative data on the subject are limited.
Dry material is normally held cold, commonly at -20 °C for long-term storage and 2 to 8 °C for working quantities, protected from light and moisture. Vials should be allowed to reach room temperature before opening so that condensation does not form on the powder. In liquid formulations the complex is generally kept near neutral to slightly acidic pH, because strongly alkaline conditions favour precipitation of copper hydroxide. Antioxidants or chelate-stabilising excipients are often added, though the specific approaches are proprietary and rarely published in detail.
| Property | Value | Notes |
|---|---|---|
| Powder storage | Minus 20 degrees Celsius, dry, dark | Desiccant used where humidity is high |
| Solution storage | Frozen, single-use aliquots | Repeated freeze-thaw cycles increase breakdown |
| Light sensitivity | Loss of intact complex under prolonged light | Amber or opaque containers reduce exposure |
| Copper assay | ICP-MS or atomic absorption spectroscopy | Reports total copper, not the fraction bound to peptide |
| Purity assay | Reversed-phase HPLC with UV or MS detection | States whether purity refers to peptide peaks or to metal content |
GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine, a short sequence of three amino acids. The peptide was first isolated from human plasma in 1973 during research on factors that influence tissue repair in liver. Its ability to bind copper ions became a central point of interest because the metal changes the peptide's chemistry and its behaviour in laboratory systems. Today the compound appears in cosmetic formulations, cell-culture studies, and biochemistry literature under several names.
The peptide sequence places a histidine in the middle, and this residue dominates metal binding. Copper(II) coordinates through the imidazole nitrogen of histidine and the terminal amino group, forming a stable chelate ring system. Loss of the copper ion leaves the free tripeptide, which has different solubility and reactivity. This structural detail matters because assays that measure only the peptide backbone can miss whether copper is still bound to it.
Several names circulate for the same material, which complicates literature searches. Cosmetic ingredient lists often use copper tripeptide-1, while older biochemistry papers use glycyl-L-histidyl-lysine or its abbreviation GHK. The copper complex is sometimes written as GHK-Cu(II) to make the oxidation state explicit. Terminology is not fully standardized, so matching a compound across sources requires attention to the exact sequence, the counterion, and the stated copper content. Reviews that compare studies must account for these naming differences before drawing conclusions.
Discovery of GHK is generally attributed to work in the 1970s that isolated a plasma factor influencing liver cell behavior. Subsequent studies identified the copper-binding tripeptide and its ability to chelate copper with high affinity. Early reports linked the complex to wound healing and tissue remodeling in animal models. The free peptide and the copper-bound form have different properties, so the two are distinguished in the literature. Whether endogenous GHK-Cu serves a single primary physiological role remains an open question.
The molecular weight and charge of GHK-Cu depend on the pH and the number of coordinated ligands. At neutral pH, the peptide typically binds one copper ion, but ternary complexes with other biomolecules can form. Spectroscopic methods such as electron paramagnetic resonance and circular dichroism are used to study the coordination environment. Reports on the exact geometry vary because the complex is dynamic in solution. Researchers often use synthetic GHK-Cu rather than extracted material to control stoichiometry and purity.
Proposed mechanisms for copper peptide activity center on delivery of copper ions to cells and on peptide fragments acting as signaling molecules. Copper is a cofactor for enzymes involved in collagen cross-linking and antioxidant defense, and the peptide may improve its availability at target sites. Separately, the tripeptide and its breakdown products have been reported to influence gene expression in cultured fibroblasts. Much of this evidence comes from laboratory cell cultures and animal models rather than controlled human trials. The relative contribution of the copper ion and the peptide sequence is therefore not fully settled.
Stability depends on temperature, light exposure, moisture, and the presence of oxidizing or reducing agents. Solid material held dry and protected from light is generally more stable than aqueous solutions, which can undergo gradual degradation. Recommended storage in much of the literature is a freezer at around minus twenty degrees Celsius for long-term retention, with working aliquots kept cold and shielded from light. Repeated freeze-thaw cycles and alkaline pH are commonly noted as factors that accelerate loss of the intact complex, though exact degradation rates vary.
Analytical confirmation usually combines a separation method with a copper-specific measurement. Liquid chromatography or mass spectrometry establishes peptide identity and purity, while an elemental measurement quantifies the metal content. A frequent misconception is that any blue solution contains an intact copper peptide complex; color alone does not confirm structure, because free copper salts and degraded mixtures can also appear colored. Literature on efficacy is mixed, with in vitro findings often more dramatic than human evidence, and reviews note small sample sizes and short follow-up. Open questions include optimal concentration, skin penetration, and long-term effects.
== Research misconduct == In September 2024, Masliah's work came under intense scrutiny when an investigation led by the journal Science exposed extensive image manipulation across 132 of his published research papers. A 286-page dossier compiled by forensic analysts and neuroscientists pointed to repeated instances of Western blot manipulation, image reuse, and other forms of digital editing across decades of his research. These allegations involved crucial studies related to Alzheimer's and Parkinson's disease, particularly surrounding the alpha-synuclein protein. The dossier was sent to the HHS Office of Research Integrity, which requested that the National Institute on Aging (NIA) start a research misconduct investigation in May 2023. The NIA started their investigation in December 2023. In September 2024, the NIH confirmed that Masliah was no longer leading the Division of Neuroscience at the NIA, following the conclusion of their investigation. The controversy includes papers that have influenced clinical trials and investment decisions in the pharmaceutical industry. 238 active patents cite papers by Masliah that contain anomalous images and data. A notable impact on the pharmaceutical industry concerns the experimental Parkinson's drug prasinezumab, developed by Prothena Biosciences in collaboration with Roche. A Phase II study reported in August 2022 found no statistically significant effect from the drug vs placebo on measures of Parkinson's disease progression. Several papers foundational to the development of prasinezumab were flagged for image manipulation.
The lamp was a small component in his system of electric lighting, and no more critical to its effective functioning than the Edison Jumbo generator, the Edison main and feeder, and the parallel-distribution system. Other inventors with generators and incandescent lamps, and with comparable ingenuity and excellence, have long been forgotten because their creators did not preside over their introduction in a system of lighting.
In his public letter of resignation, he cited his reasons as being the lack of "the possibility of fulfilling, with the necessary total transparency, autonomy, and freedom, what Cuban Masonic legislation defines as required to carry out this responsibility." Alfonso Vidal said that the Grand Lodge was in the practice of "distorting Masonic Law." He also noted that because he had signed Decree 634, it was virtually impossible for him to have abandoned his post. He wrote that he was aware that he had been wrongfully terminated through an Extraordinary Session of the Supreme Court of Masonic Justice, and that those who signed his tacit resignation were being ordered to do so by the State Security Unit. He lamented the nature of the "...political gangsterism that works in the Grand Lodge of Cuba." Alfonso Vidal wrote that: "Cuban Masons have the right to know that our institution is under one of the greatest attacks it has received since January 1, 1959." He called back on the events surrounding the case of Grand Commander Viñas Alonso, and the letter that Viñas Alonso had sent to President Díaz-Canel. He said that the situation since Díaz-Canel had sent the State Security Unit after Viñas Alonso, the situation in Cuban Freemasonry had become increasingly difficult to operate within as an ethical and moral Grand Master. He could not fulfill his obligations as Grand Master for the fear of what actions the Cuban state might take against him. He also urged Cuban Freemasons to reject anyone from the Cuban intelligence community to ever again gain high office in the Grand Lodge.
Sources: en.wikipedia.org
=== Atherosclerosis === Rapamycin can accelerate degradation of oxidized LDL cholesterol in endothelial cells, thereby lowering the risk of atherosclerosis. Oxidized LDL cholesterol is a major contributor to atherosclerosis.
There are frequent misconceptions within both patients and doctors about how hormone replacement therapy affects fertility. One common misconception is that starting it automatically leads to infertility. While it may impact the ability to be fertile, it does not mean it leads to a hundred percent infertility rate. There have been numerous cases of transgender men experiencing pregnancy and abortion. As trans men and doctors can be under this misconception about hormone replacement therapy impacting fertility and serving as a form of contraception, keeping people informed on fertility options remains crucial. For trans women, it is possible for them to undergo cryopreservation before starting hormone replacement therapy. As evidence has shown that trans women tend to have lower motile sperm compared to their cisgender counterparts, fertility preservation can be important for individuals anticipating having biological children in the future. While fertility preservation is important to consider before starting HRT, it is possible in some cases to regain fertility after halting HRT for a period of time. It is also important to educate transgender youth on their fertility preservation options. This is because few adolescents end up doing so, alongside transgender adolescents reporting distress at the prospect of becoming infertile due to medical conditions and treatment relating to their transgender identity.
Testing for CJD has historically been problematic, due to the nonspecific nature of early symptoms and difficulty in safely obtaining brain tissue for confirmation. The diagnosis may initially be suspected in a person with rapidly progressing dementia, particularly when it is also found with the characteristic medical signs and symptoms such as involuntary muscle jerking, difficulty with coordination/balance and walking, and visual disturbances. Further testing can support the diagnosis and may include:
Sources: en.wikipedia.org
The colour depends on copper held in a specific coordination environment. When the complex dissociates or the peptide is cleaved, that environment changes and the visible absorption weakens.
Frozen solutions are generally less stable than dry powder, and repeated thawing accelerates breakdown. Storage temperature, concentration and buffer composition all shift the rate, so no single figure applies to every preparation.
Chromatography separates and quantifies peptide species but does not report metal content. A separate elemental measurement is needed to show how much copper is present.
Dry powder is best kept cold, dark and sealed, typically at -20 °C for long-term storage or 2 to 8 °C for material in regular use. Vials should be warmed to room temperature before opening to prevent moisture condensing on the contents. Aqueous stock solutions degrade faster and are usually prepared fresh.